Helico Bio Enters Liquidation After Research Fails to Deliver

Helico Bio, a deep tech startup based in Auckland, has been placed into liquidation following an inability to produce expected results from its research on therapeutic compounds derived from plants. The company, which operated under the name Rau Bio Limited, was notably backed by Callaghan Innovation and Icehouse Ventures. The decision to liquidate was made by a special resolution of its shareholders on December 19, 2023.

According to the liquidators’ initial report, the primary reasons for Helico Bio’s winding up include an inability to achieve anticipated outcomes from its research and development activities, coupled with increasing obligations to creditors. The firm faced a diminished capacity to secure new capital, raising serious concerns about its financial viability.

Funding and Ambitious Goals

Helico Bio had garnered significant attention with its ambitious goal of producing “edible medicine.” The startup aimed to enhance the accessibility and affordability of essential medicines through innovative agricultural methods. A previous article from Callaghan Innovation highlighted the company’s focus on using low-tech agriculture to grow high-value therapeutic compounds, with insulin identified as its first target for proving the concept.

The company received substantial support from Callaghan Innovation, which included the R&D Experience Grant to help recruit lead bioinformatics engineers and the R&D Career Grant for postdoctoral students. Co-founder Ilya Vensky previously expressed aspirations to reposition New Zealand’s agricultural narrative towards specialized research and development, stating that the opportunity to cultivate desirable compounds aligned with the country’s strengths and market potential.

Challenges and Uncertain Future

Despite the promising vision, challenges arose when the research did not yield the expected results, leading to a loss of potential funding for further product development. Stan Denisenkov, an analyst from Waterstone, noted that the issues were specifically related to the research rather than market demand. He emphasized that the failure to secure funding was directly tied to the company’s inability to demonstrate viable results.

While the number of creditors and the total debt owed remains unknown, the liquidators have not yet disclosed the value of the company’s assets, which include patents, trademarks, and physical property. Helico Bio’s website is currently inactive, displaying a 404 error, indicating the company’s abrupt halt in operations.

As Helico Bio navigates this challenging situation, the future for its founders, investors, and employees remains precarious. The startup’s liquidation serves as a reminder of the inherent risks in the pursuit of innovation, particularly in the complex field of biopharmaceuticals.